ImmuPharma's CEO is Tim McCarthy, appointed in Jul 2021, has a tenure of 5.08 years. total yearly compensation is £294.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth £59.54K. The average tenure of the management team and the board of directors is 3.9 years and 10.9 years respectively.
Key information
Tim McCarthy
Chief executive officer
UK£294.0k
Total compensation
CEO salary percentage
100.00%
CEO tenure
5.1yrs
CEO ownership
0.2%
Management average tenure
3.9yrs
Board average tenure
10.9yrs
Recent management updates
Recent updates
CEO Compensation Analysis
How has Tim McCarthy's remuneration changed compared to ImmuPharma's earnings?
Date
Total Compensation
Salary
Company Earnings
Dec 31 2025
UK£294k
UK£294k
-UK£2m
Sep 30 2025
n/a
n/a
-UK£3m
Jun 30 2025
n/a
n/a
-UK£4m
Mar 31 2025
n/a
n/a
-UK£3m
Dec 31 2024
UK£294k
UK£294k
-UK£2m
Sep 30 2024
n/a
n/a
-UK£2m
Jun 30 2024
n/a
n/a
-UK£2m
Mar 31 2024
n/a
n/a
-UK£3m
Dec 31 2023
UK£294k
UK£294k
-UK£3m
Sep 30 2023
n/a
n/a
-UK£3m
Jun 30 2023
n/a
n/a
-UK£3m
Mar 31 2023
n/a
n/a
-UK£3m
Dec 31 2022
UK£107k
UK£107k
-UK£4m
Sep 30 2022
n/a
n/a
-UK£5m
Jun 30 2022
n/a
n/a
-UK£6m
Mar 31 2022
n/a
n/a
-UK£7m
Dec 31 2021
UK£575k
UK£287k
-UK£8m
Sep 30 2021
n/a
n/a
-UK£8m
Jun 30 2021
n/a
n/a
-UK£8m
Mar 31 2021
n/a
n/a
-UK£7m
Dec 31 2020
UK£260k
n/a
-UK£7m
Sep 30 2020
n/a
n/a
-UK£6m
Jun 30 2020
n/a
n/a
-UK£5m
Mar 31 2020
n/a
n/a
-UK£6m
Dec 31 2019
UK£260k
n/a
-UK£6m
Compensation vs Market: Tim's total compensation ($USD396.84K) is about average for companies of similar size in the UK market ($USD416.67K).
Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.
CEO
Tim McCarthy (70 yo)
5.1yrs
Tenure
UK£294,000
Compensation
Mr. Timothy Paul McCarthy, XIV, MBA, FCCA, also known as Tim, had been Independent Non-Executive Chairman at 4basebio PLC until 2025. He co-founded Alizyme PLC in 1995. Mr. McCarthy serves as the Chairman...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Timothy McCarthy
Chairman & CEO
5.1yrs
UK£294.00k
0.24% £ 59.5k
Timothy Franklin
COO & Director
6.6yrs
UK£252.00k
0.084% £ 21.0k
Sebastien R. Goudreau
Chief Scientific Officer & Director
less than a year
UK£3.00k
0.024% £ 6.0k
Lisa Baderoon
Head of Investor Relations & Non Executive Director
14.5yrs
UK£132.00k
0.25% £ 63.4k
Ashley Clarke
Group CFO & Company Secretary
1.7yrs
no data
no data
Jean-Marie Geiger
Head of Clinical Development
no data
no data
no data
Laura Mauran-Ambrosino
Head of Research & Development
3.9yrs
no data
no data
Lara Sucheston-Campbell
Head of Clinical & Medical Affairs
3.5yrs
no data
no data
3.9yrs
Average Tenure
61yo
Average Age
Experienced Management: IMML's management team is considered experienced (3.9 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Timothy McCarthy
Chairman & CEO
10.9yrs
UK£294.00k
0.24% £ 59.5k
Timothy Franklin
COO & Director
5.1yrs
UK£252.00k
0.084% £ 21.0k
Sebastien R. Goudreau
Chief Scientific Officer & Director
3yrs
UK£3.00k
0.024% £ 6.0k
Lisa Baderoon
Head of Investor Relations & Non Executive Director
5.1yrs
UK£132.00k
0.25% £ 63.4k
Lee Simon
Member of Scientific Advisory Board
13.1yrs
no data
no data
Vibeke Strand
Member of Scientific Advisory Board
13.1yrs
no data
no data
Ketan Patel
Independent Non-Executive Director
less than a year
UK£10.77k
no data
David Isenberg
Member of Scientific Advisory Board
13.1yrs
no data
no data
Daniel Wallace
Member of Scientific Advisory Board
13.1yrs
no data
no data
Cees Kallenberg
Member of Scientific Advisory Board
13.1yrs
no data
no data
Laurence Reilly
Senior Independent Non-Executive Director
3yrs
UK£50.00k
no data
10.9yrs
Average Tenure
61yo
Average Age
Experienced Board: IMML's board of directors are seasoned and experienced ( 10.9 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/08/09 16:23
End of Day Share Price
2026/08/06 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ImmuPharma plc is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.